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HES6 drives a critical AR transcriptional
programme to induce castration-resistant prostate
cancer through activation of an E2F1-mediated
cell cycle network
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Abstract
Castrate-resistant prostate cancer (CRPC) is poorly characterized
and heterogeneous and while the androgen receptor (AR) is of
singular importance, other factors such as c-Myc and the E2F
family also play a role in later stage disease. HES6 is a transcription
co-factor associated with stem cell characteristics in neural tissue.
Here we show that HES6 is up-regulated in aggressive human
prostate cancer and drives castration-resistant tumour growth in
the absence of ligand binding by enhancing the transcriptional
activity of the AR, which is preferentially directed to a regulatory
network enriched for transcription factors such as E2F1. In the
clinical setting, we have uncovered a HES6-associated signature
that predicts poor outcome in prostate cancer, which can be phar-
macologically targeted by inhibition of PLK1 with restoration of
sensitivity to castration. We have therefore shown for the first
time the critical role of HES6 in the development of CRPC and
identified its potential in patient-specific therapeutic strategies.
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Introduction
Prostate cancer is the most common non-cutaneous malignancy in
men in western countries (CRUK, 2010). Death results from the
development of castrate-resistant prostate cancer (CRPC). Several
mechanisms have been proposed to explain how this aggressive
phase of the disease develops. Most depend on continued androgen
receptor (AR) signalling in the context of enhanced secondary
pathways, while others are independent of conventional AR activity
(Pienta & Smith, 2005; Lamb et al, 2014). This heterogeneity
explains why, although virtually all primary locally advanced pros-
tate cancer can be treated effectively with androgen deprivation
therapy (ADT), CRPC remains difficult to treat, and those therapies
that have been developed are only effective for a limited duration in
a limited set of patients (Yap et al, 2011). It is therefore critical that
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we understand more about the driving processes in CRPC, so that
patient-specific mechanisms can be targeted.
Various oncogenic factors have been implicated in the natural
history of prostate cancer. The AR has generally been accepted as
the pre-eminent driving protein in prostate cancer and, even in
hormone resistant prostate cancer, it is still implicated in several
escape mechanisms based on a non-dihydrotestosterone-bound-AR
(Pienta & Smith, 2005; Lamb et al, 2014). c-Myc has been found
to be amplified in more than half of refractory prostate cancers
(Bernard et al, 2003; Clegg et al, 2011) and has been identified as
one of the key players in cell potency (Takahashi et al, 2007), but
the factors which mediate its downstream effects in late-stage
prostate cancer are still not well understood. Deregulation of E2F
activity and early cell cycle progression has also been implicated in
aggressive prostate cancer (Sharma et al, 2010), but the precise role
of E2Fs in cancer is dependent on a balanced interplay with other
regulatory factors and these interactions in prostate cancer need to
be elucidated.
The study of transcription factors in cell pluripotency has shown
that a small number of master regulator transcription factors can
radically change cell phenotype (Takahashi et al, 2007). HES6 has
been identified as a regulator of stem cell fate, specifically in neuro-
genesis (Kageyama et al, 2005; Murai et al, 2011), myogenesis
(Malone et al, 2011) and gastrulation (Murai et al, 2007, 2011). In
addition, it has been described as a marker of the neuroendocrine
phenotype in prostate cancer (Vias et al, 2008) and in metastatic
breast cancer (Hartman et al, 2009). Most recently, work demon-
strating the cooperation of HIF-1a and FoxA2 in metastatic neuro-
endocrine prostate cancer has identified HES6 as an important factor
in the development of these tumours (Qi et al, 2010).
Here, we evaluate the role of HES6 in CRPC and propose a mech-
anism of action in which HES6 induces persistent AR signalling and
enhanced E2F1-mediated cell cycle activity. In the clinical setting,
we describe a HES6-associated gene signature that correlates with
poor outcome and outline a possible therapeutic strategy to target
this programme of resistance.
Results
HES6 is regulated by AR and c-Myc
Using the androgen-dependent LNCaP cell line and chromatin
immunoprecipitation sequencing (ChIPseq), we showed that two
potent oncogenes in prostate cancer, the AR (Massie et al, 2011)
and c-Myc, bind upstream of the HES6 coding sequence (Supple-
mentary Fig S1A) to positively regulate levels of HES6 mRNA
(Fig 1A, Supplementary Fig S1B and C) and confirmed that overex-
pression of c-Myc overcomes growth inhibition by bicalutamide
(Bernard et al, 2003) (Supplementary Fig S1D), an effect that can be
reversed by knock-down of HES6 (Supplementary Fig S1E).
HES6 initiates androgen-independent growth
HES6 levels are found to be raised in several independent clinical
datasets comparing aggressive disease (metastases or CRPC) with
primary tumour and benign disease (Fig 1B). Using the bicaluta-
mide/castration-resistant derivatives LNCaP-Bic (Hobisch et al,
2006), C4-2 and C4-2b cells (Thalmann et al, 1994) as models of
CRPC, we found evidence of significant increases in HES6 transcript
levels in the C4-2 derivatives compared to LNCaP controls (Supple-
mentary Fig S2A). To test the functional relevance of HES6 in the
transition to CRPC, we stably overexpressed HA-tagged HES6 in
androgen-sensitive prostate cancer LNCaP and DuCaP cells, which
induced reduced sensitivity to bicalutamide (Supplementary Fig
S2B–D). We then proceeded to surgical castration using luciferase-
labelled LNCaP cells (LNCaP-LM) subcutaneously injected into the
flanks of NOD-SCID gamma (NSG) mice. Graft size was monitored
by bioluminescent imaging over 3 months. Overexpression of HES6
was sufficient to maintain normal tumour growth (Fig 1C) after
castration. Control grafts in castrated conditions were small and
pale, while the comparable HES6 grafts were large and vascular
(Fig 1D). Knock-down of HES6 by lentiviral shRNA in C4-2b cells
(Supplementary Fig S2E) led to significant attenuation of tumour
growth in both full and castrated conditions (Fig 1E and Supplemen-
tary Fig S2F). These data show that HES6 is sufficient to produce a
castration-resistant phenotype.
Nuclear AR and cell proliferation are maintained in HES6 grafts
in castrate conditions
We next assessed intensity of nuclear AR and cell proliferation by
immunohistochemical analysis of the LNCaP grafts. Normally, the
AR shuttles in and out of the nucleus according to the extent of
ligand activation, and following removal of testosterone, the AR
localizes to the cytoplasm (Azzi et al, 2006; Cutress et al, 2008). We
demonstrated cytoplasmic relocation of the AR in the native mouse
prostate (Supplementary Fig S3A) and in control grafts following
castration. By contrast, the AR was predominantly nuclear in
castrated HES6 xenografts (Supplementary Fig S3A, quantified
in Supplementary Fig S3B), suggesting a role for nuclear AR in
HES6-driven castration-resistant grafts. Staining using the prolifera-
tion marker Ki67 showed uniform increases in the castrated
HES6-overexpressing tissue (Supplementary Fig S3A, quantified in
Supplementary Fig S3C).
HES6 rescues AR activity at a subset of Androgen Receptor
Binding Sites (ARBS) which is also enhanced in CRPC
In order to explain our discovery of nuclear AR with increased levels
of HES6 in castration, we measured AR binding to chromatin by
ChIPseq. We found during bicalutamide treatment that HES6 was
able to maintain many AR binding sites that were lost in the EV
control cells. In such inhibitory conditions, we were able to divide
AR binding sites (ARBS) into three distinct classes: first, those peaks
that were lost during AR inhibition in both EV and HES6 cells were
defined as “lost”; second, those that disappeared in EV during bica-
lutamide treatment but were clearly present with HES6 overexpres-
sion were defined as “rescued”; third, those that were never totally
lost in the EV control condition with bicalutamide but were clearly
enhanced by the presence of high HES6 were defined as “enhanced”
(Fig 2A, Supplementary Table S1). Of these 3 groups, we observed
the strongest difference in average peak height between HES6 and
EV in those defined as “rescued” (Fig 2B). This included well-
known AR responsive genes such as KLK2 and KLK3 (Fig 2C,
Supplementary Fig S4A). We made comparison with ChIPseq data
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Figure 1. HES6 induces castration-resistant growth.
A Changes in HES6 mRNA levels on alteration of AR and c-Myc activity in LNCaP cells, shown by quantitative PCR. Cells were starved in Charcoal Stripped Foetal Bovine
Serum (CS) for 72 h and treated with 10 nM R1881 (AR agonist) for 16 h to check the AR regulation of HES6. Cells transfected with a pcDNA4-Myc vector were grown
in Full Serum (FS) conditions; n = 3, error bars represent mean  s.e.m.; *P = 0.016, #P = 6.9E-6 by t-test.
B Box and whisker dot plot showing HES6 expression is increased in metastatic disease (Mets) and castrate-resistant prostate cancer (CRPC) in several public datasets
(Tomlins et al, 2005; Varambally et al, 2005; Taylor et al, 2010; Grasso et al, 2012). *P = 8.8E-6, #P = 7.9E-5 by limma with Benjamini–Hochberg adjustment for
multiple testing for comparison of Mets to Benign.
C Xenografts of HES6-overexpressing LNCaP cells are resistant to castration. LNCaP cells expressing luciferase/YFP (LNCaP-LM) and transduced to overexpress HES6
were grafted subcutaneously (2 × 106 cells) in NSG mice, and growth was monitored by bioluminescent imaging for 11 weeks. Host mice were castrated at 3 weeks
(grafts approximately 100 mm3); n = 5; error bars represent mean  s.e.m; P = 0.0002 by t-test at week 11 for comparison of EV Castr to HES6 Castr. EV = Empty
vector. Full = testes present. Castr = castration.
D Visual appearance of harvested grafts and mean weights. One xenograft of each group is shown as an illustration. Evidence of significant difference in mean graft
weight in castrated conditions (0.017  0.009 g versus 0.503  0.158 g). Scale bars = 5 mm; n = 5; error bars represent mean  s.e.m.; *P = 0.0001 by t-test.
E Androgen-insensitive C4-2b-LM xenografts showed growth attenuation with constitutive lentiviral knock-down of HES6 (shHES6) compared to non-targeting controls
(shNT). n = 5; error bars represent mean  s.e.m.; *P = 0.004 by t-test at week 7. See also Supplementary Figs S1–S3.
Source data are available online for this figure.
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Figure 2. HES6 modulates AR binding in bicalutamide and castration resistance with a shift in AR regulome.
A Heatmap of normalized signal at peak summits in a window  1 kb. Binding site classes were established by grouping highly reproducible peak calls into those that
were still present with empty vector (EV) in 1 lM bicalutamide (Bic) but “enhanced” by HES6, “rescued” by HES6 or “lost” in both conditions. Average binding site
location was established from mean location of peak summits across biological replicates and intensity of signal calculated as mean of the RPM normalized read
counts. All conditions were in biological quadruplicate as shown with the exception of EV in bicalutamide which was in triplicate. Veh = vehicle (ETOH).
B The mean normalized AR signal as profiles across binding sites seen in (A). This illustrates the global differences between conditions within the different AR binding
site classes.
C Example of binding events at KLK2 and KLK3 (PSA) where binding is markedly reduced with bicalutamide but rescued with overexpression of HES6.
D Heatmap showing binding site co-occurrence for “lost,” “rescued” and “enhanced” groups compared to global E2F1 binding sites as well as Encode Consortium
ChIPseq sets for well-known regulatory transcription factors. Comparisons were also made with our human tissue AR ChIPseq (Sharma et al, 2013). Co-occurrence
was calculated as the total base-pair overlap of occupancy between the test and query binding site sets normalized to the total base-pair occupancy of the query set.
To account for the differing lengths of the test sets, co-occurrence scores were normalized to Z-scores within each test set . Tx = treatment, HNPC = hormone naïve
prostate cancer.
E Genomic distribution analysis of “rescued” versus “lost” ARBS compared to whole genome shows increased AR binding in proximal promoters.
F Selected AR binding sites were validated by ChIP in the castrate-resistant C4-2b derivative of LNCaP cells. Knock-down of HES6 reduced AR binding enrichment at all
selected sites compared to control sites with no ChIPseq evidence of AR binding. n = 3; CAMKK2 P = 0.021, SPRY1 P = 0.026, RFC1 P = 0.056, KLK3 P = 0.041, GDF15
P = 0.008, NKX3-1 P = 0.006, TMPRSS2 P = 0.017, KLK2 P = 0.023, HIF1A P = 0.031, KLK15 P = 0.009, TLE4 P = 0.026, HES6 P = 0.018, TP63 P = 0.01, FKBP5
P = 0.006 by t-test.
G HES6-overexpressing LNCaP cells were transduced with a pSicoR lentivirus to stably knock-down AR (40% knock-down). Constitutive lentiviral knock-down of the AR
limits HES6-overexpressing LNCaP growth and abrogates the HES6-driven bicalutamide-resistant phenotype. Vehicle (Veh) is ETOH and bicalutamide (Bic) 1 lM; n = 3;
error bars represent mean  s.e.m.; *P = 0.023 by t-test for comparison of shAR Bic 1 lM to shNT Bic 1 lM. See also Supplementary Fig S4 and Tables S1 and S2.
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for other transcription factors including E2F1, c-Myc, FOXA1 and
STAT3 (Fig 2D, accessed through Encode Consortium), and found a
strong enrichment in the “rescued” group, raising the possibility of
concerted activity between the AR and these factors. Furthermore,
analysis of previous data assessing ARBS in human tissue (Sharma
et al, 2013) revealed a similar pattern of transcription factor overlap
in CRPC tissue, as well as untreated and potentially aggressive
primary prostate cancer (Fig 2D). Interrogation of the ARBS in an
unbiased manner with MEME (Machanick & Bailey, 2011) identified
similar motif enrichment (Supplementary Fig S4B and Table S2).
Analysis of ARBS genomic distribution uncovered a twofold
increase in ARBS located 500–2,000 bp upstream of transcriptional
start sites (TSS) in the “rescued” set, consistent with a small shift of
AR binding towards proximal promoters (Fig 2E).
We confirmed that this persistent AR signalling was HES6-
dependent by demonstrating evidence of reduced AR binding at
several selected ARBS with stable knock-down of HES6 in C4-2b
cells (Fig 2F). Finally, we verified that HES6-driven androgen insen-
sitivity is still AR-dependent by knocking down the AR in HES6-
overexpressing cells, with reversal of the phenotype (Fig 2G,
Supplementary Fig S4C). Collectively this suggests modulation of
the AR regulome by HES6.
HES6, AR and E2F1 co-operate in driving a cell cycle-related
tumour-enhancing network
We used expression microarrays to identify differentially expressed
genes (DEGs) associated with HES6 overexpression in the castration-
resistant xenografts (Fig 3A, Supplementary Fig S5) and Ingenuity
Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com)
to infer the functional consequences (Supplementary Fig S6A).
Surprisingly, we did not find any evidence for a neuroendocrine
phenotype (Supplementary Fig S5) but rather a predominance for
cell cycle pathways. A combined cell cycle network from the input
gene list revealed several dominant clusters including E2Fs, CDKs,
Cyclins and Aurora kinases (AURK) (Supplementary Fig S6B).
In order to identify potential transcriptional intermediaries, we
assessed enriched binding motifs by in silico analysis (Supplemen-
tary Fig S6C and Table S3) of the DEGs from castrated xenografts as
well as HES6-overexpressing LNCaP cells. This identified strong
enrichment for E2F family binding sites and specifically for
E2F1 (Fig 3B). Furthermore, we found a strong overlap (44%)
between DEGs in castrated xenografts and E2F1 transcriptional
targets identified by ChIP-seq in LNCaP cells (Fig 3C). To identify
whether the presence of HES6 has a specific effect on E2F function,
we performed ChIPseq for E2F1 (n = 4) in LNCaP cells and found
that HES6 increased average E2F1 binding activity in the presence of
bicalutamide (Fig 3D). Given our previous findings suggesting a shift
in AR binding towards promoter regions when “rescued” by HES6 in
bicalutamide, we investigated whether AR and E2F1 could be inter-
acting and whether HES6 was able to modulate such interaction. We
found that the ARBS belonging to the “enhanced” and “rescued”
groups showed a clear increase in AR occupancy at E2F1 binding
sites (Fig 3E). Enrichment of E2F1 binding in cells overexpressing
HES6 was validated at promoters of selected E2F1 transcriptional
targets (Fig 3F and Supplementary Fig S7) and was found not to be a
consequence of increased E2F1 protein levels (Fig 3F and Supple-
mentary Fig S5). We reasoned that HES6 may be enhancing E2F
activity and investigated potential interactions between HES6 and
E2F1. Given the persistence of nuclear AR with HES6, we also evalu-
ated interactions with the AR. We demonstrated physical interaction
between HES6 and E2F1, as well as between the AR and E2F1
(Fig 3G). These findings indicate that HES6 may enhance concerted
E2F1 and AR activity in androgen-deprived conditions.
E2F1 is a final common regulator for G1/S cell cycle transition
(Cam & Dynlacht, 2003). We therefore assessed by FACS analysis
the effect of overexpressing HES6 on cell cycle distribution in LNCaP
cells and observed an increase in the fraction of cells in both S and
G2/M phases (Supplementary Fig S8A). To test whether this was
due to more rapid initiation of cell cycle activity, we observed cell
cycle fractions after synchronization (Supplementary Fig S8B-D)
and found more rapid cell cycle re-entry in HES6-overexpressing
cells in both normal conditions and bicalutamide.
HES6 has a corresponding signature associated with aggressive
clinical disease
To assess the clinical relevance of these findings, we used publicly
available data (Varambally et al, 2005) to make comparisons
between benign, primary and metastatic prostate cancer. We found
that the cell cycle genes associated with HES6 expression (from
Fig 3A) were strongly represented in the metastatic group (Supple-
mentary Fig S9). We interrogated these data to identify transcripts
most strongly correlated with HES6 and selected the top 1.5%
according to a cut-off correlation coefficient of 0.9 (Supplementary
Fig S10A). From these 788 genes, we selected those that were also
present in the castrated HES6-overexpressing LNCaP xenograft DEG
list. The combination of these two sets of data (one from human
samples, one from xenografts overexpressing HES6) generated a
“HES6-associated signature” of 222 transcripts (Supplementary
Table S4). In order to validate this signature, we studied three addi-
tional publicly available datasets (Tomlins et al, 2005; Taylor et al,
2010; Grasso et al, 2012) and a published cell cycle progression
signature (CCP) in CRPC (Cuzick et al, 2011). Allowing for differ-
ences in array coverage, we found that genes on this HES6-associ-
ated signature list were consistently enriched in DEG lists comparing
metastatic or castrate-resistant tumours with benign or normal tissue
(Supplementary Fig S10B and C). These HES6-correlated genes effec-
tively clustered men into two groups following radical prostatectomy
(Taylor et al, 2010) (Fig 4A). Kaplan–Meier analysis at a mean
follow-up of 4.5 years (range 2–149 months) showed clear partition-
ing for men with low versus high HES6 (Fig 4B). Use of the n = 222
HES6-associated signature further enhanced clustering and was even
more effective in differentiating those patients destined for early
relapse (Fig 4C). This signature is more powerful in this capacity
than PSA and Gleason score (Fig 4D and Supplementary Fig S11). In
the absence of good HES6 antibodies that are reliable for immunohis-
tochemistry (Hartman et al, 2009), we checked protein expression of
the HES6-associated cell cycle regulator polo-like kinase 1 (PLK1) in
representative samples of benign, primary prostate cancer and CRPC
tissue (Fig 4E), identifying strong expression in CRPC tissue only.
We quantitatively assessed PLK1 expression in a large novel human
tissue microarray incorporating 61 men, some of whom had andro-
gen naı¨ve prostate cancer while others had hormone-relapsed
disease. We found clear evidence for an increase in PLK1 expression
in the prostates of men with CRPC (Fig 4F).
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Figure 3. HES6 enhances a cell cycle network through concerted activity with E2F1 and AR.
A Selection of differentially expressed genes (DEGs) in castrated xenografts of HES6-overexpressing LNCaP cells (orange) versus castrated EV controls (green); n = 5.
B GSEA motif analysis revealed enrichment of E2F1 in DEGs associated with HES6-overexpressing cells. Xenograft GSEA-NES-value = 2.25 and cells in vitro GSEA-NES-
value = 2.09.
C Overlap of the DEGs from castrated HES6-overexpressing LNCaP xenografts with E2F1 targets. Nearest gene ( 25 kb) overlap with DEGs from castrated (Castr) HES6-
overexpressing LNCaP xenografts is shown; hypergeometric P-value = 2.53E-46.
D Average enrichment of E2F1 at target sites is increased with HES6 compared to EV in bicalutamide (Bic) but not vehicle (Veh, ETOH). All ChIPseqs n = 4.
E AR ChIPseq occupancy at E2F1 binding sites is increased in HES6 “enhanced” and “rescued” peaks compared to “lost” (see Fig 2).
F Heatmap showing E2F1 ChIP. HES6 increased binding of E2F1 to differentially expressed genes in the castrated xenografts of HES6-overexpressing LNCaP cells. Each
ChIP n = 3; Myc P = 0.052, AURKB P = 0.057, CDC2 P = 0.12, AURKA P = 0.087, UBE2C P = 0.165, CENPM P = 0.049, CDK4 P = 0.025, BUB1 P = 0.068, CDC20
P = 0.087 by t-test.
G HES6 and AR co-immunoprecipitate with E2F1. IPs for AR, E2F1, HES6 and control IgG were performed using HES6HA-overexpressing LNCaP cell extracts and blotted
for HA, E2F1 and AR. n = 5. One representative experiment is shown for illustration. SN = supernatant. IP = immunoprecipitate. Different time exposures of the same
membrane are shown for each blot section to better visualize the whole experiment and are indicated in the lower-left corner (‘= minutes and “= seconds). Arrows
indicate co-IP of HES6 and E2F1. See also Supplementary Figs S5–S8 and Table S3.
Source data are available online for this figure.
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Selective pharmacological inhibition of this mechanism of
androgen independence
Finally, we investigated whether inhibition of HES6-driven cell cycle
regulating genes could alter growth in these castration-resistant
HES6-overexpressing cells. We found that these cells, though resis-
tant to bicalutamide, were responsive to inhibition with the PLK1
inhibitor GSK461364A (Gilmartin et al, 2009) with a greater than
50% reduction in cell proliferation (Supplementary Fig S12A).
Indeed, concomitant application of this inhibitor with bicalutamide
further reduced the rate of cell growth suggesting a synergistic effect
to rescue the androgen-dependent phenotype. These findings were
recapitulated in vivo with intraperitoneal injection of drug dramati-
cally slowing castrate-resistant growth of LNCaP-LM-HES6
xenografts (Fig 4G). PLK1 inhibition also reduced growth of
castrate-resistant AR-positive cells (C4-2b) and AR-negative cells
(PC3) (Supplementary Fig S12B and C) with greater effects on PC3
cells on isogenic introduction of the AR (Nelius et al, 2007). This
suggests that PLK1 inhibition reverses HES6-driven castration resis-
tance and raises the possibility of synergy with AR activity.
Discussion
Clinical progression to castrate-resistant prostate cancer (CRPC)
remains a major clinical problem and is the cause of death for most
men dying of prostate cancer. Half of men on LHRH monotherapy
will progress within 2 years of treatment (Hellerstedt & Pienta,
2002), and survival after the onset of metastatic CRPC does not
usually extend beyond 6–12 months (Petrylak et al, 2004). Recent
developments in second-/third-line prostate cancer therapeutics
with wide-ranging modes of action have reinforced the concept that
castrate-resistant prostate cancer is a heterogeneous disease with
multiple mechanisms of resistance (de Bono et al, 2010, 2011; Kantoff
et al, 2010; Nilsson et al, 2011; Scher et al, 2012; Ryan et al, 2013).
It is therefore important that cancer researchers delineate fully
these different mechanisms. Our study outlines a mechanism of
resistance centred on a single transcription co-factor and shows how
hypothesis-driven investigation of cell function, combined with
large-scale genomic correlation, can deliver a candidate oncogenic
factor in a meaningful biological context with the potential to
uncover new therapeutic avenues that could improve the treatment
of men who are no longer responsive to current drugs.
We have identified HES6 as a transcription co-factor that is able
to alter prostate cancer cell phenotype so fundamentally that these
cells are able to grow in the absence of testosterone. HES6 is better
known for its functions in the nervous system, where it is thought
to promote neuronal differentiation (Kageyama et al, 2005; Murai
et al, 2011), but its role in the prostate cell is not yet well under-
stood. Here we have seen that HES6, a driver of androgen indepen-
dence, is itself regulated by the AR. This suggests that the AR
regulome includes factors that are not necessarily required for
growth in a normal environment, but which can be recruited in an
altered environment where the cell has to rely on other pathways
for survival (Mills, 2014). Recently, it has been shown that ETS
factors such as ERG markedly increase AR binding in mouse pros-
tate tissue and mediate robust transcriptional changes in PTEN null
prostate cancer cells (Chen et al, 2013). In our study, we describe
how, during castration or AR inhibition, HES6 overexpression can
modulate the AR regulome, maintaining chromatin binding at a
proportion of ARBS in the absence of hormone stimulation. We also
show c-Myc to be another regulator of HES6 transcription, and so
have identified two potent oncogenes involved upstream of HES6 in
this mechanism of androgen independence.
Our study identifies E2F1 as an important intermediary in this
process, with E2F-regulated cell cycle factors accounting for a large
proportion of differentially expressed genes in these castrate-
resistant tumours. This cell cycle enhancing framework fits with
other recent studies providing evidence for the centrality of cell
cycle genes in explaining mechanisms of resistance (Sharma et al,
2010) and predicting poor survival in the clinical setting (Cuzick
et al, 2011). We identify a novel interaction between HES6 and
E2F1 and E2F1 and the AR and show enhancement of E2F1 activity
that seems to result from protein complex formation rather than
increased E2F1 expression as previously found in breast cancer
(Hartman et al, 2009). We propose that this mechanism may
account for maintained prostate cancer cell growth through
concerted activity with the AR in HES6-driven androgen insensitiv-
ity, where the AR persistently binds to chromatin at a subset of
binding sites and seems to be essential for the survival of the resis-
tant cells, which cannot withstand AR knock-down. This finding is
consistent with previous work assessing the impact of AR knock-
down on castration-resistant derivatives of this model (Snoek et al,
2009).
Although we did not find evidence for a classical neuroendocrine
phenotype, recent studies have suggested a broader relevance for
neuroendocrine differentiation with powerful transcription factors
such as Myc and cell cycle regulators such as AURKA being impli-
cated in development of therapy resistant tumours bearing neuro-
endocrine characteristics (Beltran et al, 2011).
We used a robust independent model to derive a HES6-associated
gene signature which contained several factors, including UBE2C
(Wang et al, 2009), EZH2 (Xu et al, 2012), and cell cycle progres-
sion factors such as CDC20, TK1, PLK1 and PTTG1 already shown
to be important in CRPC (Cuzick et al, 2011). We have found that
HES6-driven genes are strongly associated with aggressive human
prostate cancers at their presentation, demonstrating that this
phenomenon is not confined to the laboratory setting or to cell lines
alone. Furthermore, in patients undergoing radical treatment, this
signature is associated with early biochemical relapse after surgery.
We have identified PLK1 as a possible target within this gene
signature with an inhibitor giving promising results in rescuing an
androgen-sensitive phenotype and halting CRPC cell growth. When
combined with our data suggesting poor survival in patients who
have raised levels of HES6 and its associated genes, this raises the
possibility that such molecular information could be used to stratify
patients for trials of a PLK1 inhibitor. In future, a more personalized
treatment strategy could be pursued with men who display a high-
risk molecular signature being monitored closely and offered early
adjuvant treatment, while those at lower risk could be managed
more expectantly in order to avoid unnecessary intervention.
Taken together, our results identify the critical role of the HES6
transcription co-factor in maintaining AR activity in CRPC with
concerted enhancement of E2F1 activity to maintain cell growth in
the absence of testosterone and thereby offer a fresh treatment
paradigm in combating this disease.
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Materials and Methods
Detailed methodology and details of antibodies, primers, probes and
oligonucleotides are described in Supplementary Methods.
Plasmids
c-Myc was amplified from an IMAGE clone (Lawrence Livermore
National Laboratory, Livermore, CA) and then inserted at the
BamH1 restriction site of the lentiviral inducible pLVX-Tight-Puro
vector (Clontech, Mountain View, CA) by IN-Fusion Advantage
(Clontech) homologous fusion. Lentiviral pLVX-Teton-Genet vector
(Clontech) was used to stably express the tetracycline-controlled
transactivator. The human HES6 cDNA sequence was amplified and
inserted into the retroviral vector pBabe-puro (Cell Biolabs, San
Diego, CA). For knock-down of HES6, annealed oligonucleotides
were inserted into the lentiviral pSicoR vector (Ventura et al, 2004)
with a puromycin resistance cassette. Knock-down of the AR was
achieved using the lentiviral pSicoR vector with a blasticidin resis-
tance cassette.
Mice
Immunocompromised NSG male mice (Charles River, Wilmington,
MA) were used for tumour implantation. GSK461364A was adminis-
tered intraperitoneally 50 mg/kg at a dose rate of q2dx12. Vehicle
was water with 2% Cremophor-EL and 2% N,N-dimethylacetamide
(DMA) (Sigma-Aldrich, St. Louis, MO). Mice were maintained in the
Cancer Research UK Cambridge Institute Animal Facility. All experi-
ments were performed in accordance with national guidelines and
regulations, and with the approval of the animal care and use
committee at the institution.
Gene expression data
IlluminaBeadChip HumanWG-12 (version 3 and 4; Illumina, San
Diego, CA) were used for the gene expression. Publicly available
prostate cancer data sets were downloaded from GEO (Gene Expres-
sion Omnibus). Biological function and network generation was
performed using Ingenuity Pathway Analysis (IPA, Ingenuity
Systems, Redwood City, CA). For enrichment and motif analysis, we
used GSEA (Mootha et al, 2003; Subramanian et al, 2005).
Human prostate tissue samples
Ethical approval for the use of samples and data collection was
granted by the local Research Ethics Committee under ProMPT
(Prostate Mechanisms for Progression and Treatment) “Diagnosis,
investigation and treatment of prostate disease” (MREC 01/4/061).
Statistics
Data from independent experiments were reported as the
mean  s.e.m. Student’s t-test analysis or Mann–Whitney U-test
were performed to determine statistical significance in replicate
comparisons and Fisher’s exact test for proportionate analyses.
Study approval
All animal procedures were carried out in accordance with Univer-
sity of Cambridge and Cancer Research UK guidelines under UK
Home Office project licenses 80/2301 and 80/2435. For human
material, informed written consent was received from participants
prior to inclusion in the study under ethics committee number
MREC 01/4/061.
Accession numbers
Study data are deposited in NCBI GEO under accession number
GSE36526.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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Figure 4. HES6 is associated with aggressive clinical disease targetable by PLK1i.
A HES6-associated signature (n = 222, see Supplementary Fig S10 and Table S4 for generation of n = 222 HES6-associated signature) used to cluster 140 prostatectomy
specimens (Taylor et al, 2010). See also Supplementary Fig S9.
B Kaplan–Meier biochemical relapse-free survival analysis by recursive partitioning to high and low expression of HES6. Logrank P-value.
C Kaplan–Meier biochemical relapse-free survival analysis by two cluster partitioning based on expression of HES6-associated signature (n = 222). Logrank P-value.
D Graphical representation of proportional hazard ratios for biochemical relapse (BCR) calculated by Cox regression models used to estimate the association with
relapse of several key variables: age, surgical margin status, PSA, Gleason score and the clusters generated by the HES6-associated signature. Both the signature and
the Gleason score were shown to have an independent prognostic effect (P = 0.0071 and P = 0.0208), but not PSA (P = 0.7384), SMS (P = 0.1467) and age of
diagnosis (P = 0.9180). See also Supplementary Fig S11.
E Protein expression of HES6-responsive gene PLK1 shows strong staining in CRPC alone, compared to primary prostate cancer (CaP) and benign control (benign
prostatic hyperplasia, BPH). Scale bars represent 250 lm. Magnified windows = 100 lm2.
F Quantification of PLK1 expression in a hormone-relapsed tissue microarray (HRTMA). Cores were taken from 45 men with varying degrees of androgen insensitivity
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positive nuclei. There was increased PLK1 staining in men resistant to androgen therapy; P-value = 2.189E-13 by Fisher’s exact test. LHRH = luteinizing hormone
releasing hormone. CAB = complete androgen blockade.
G LNCaP-LM-HES6HAHA xenografts were sensitized to castration on treatment with selective polo-like kinase 1 (PLK1) inhibitor GSK461364A 50 mg/kg administered i.p.
at a dose rate of q2dx12 versus vehicle. Host mice were castrated at 3 weeks (grafts approximately 100 mm3); n = 8; error bars represent mean  s.e.m.; *P = 0.007
by Mann–Whitney U-test at week 12. See also Supplementary Figs S9–S12 and Table S4.
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